These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10430096)

  • 1. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.
    Hong RL; Spohn WH; Hung MC
    Clin Cancer Res; 1999 Jul; 5(7):1884-91. PubMed ID: 10430096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
    Zhang L; Chang CJ; Bacus SS; Hung MC
    Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
    Zhang L; Hung MC
    Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
    Hwang MS; Yum YN; Joo JH; Kim S; Lee KK; Gee SW; Kang HI; Kim OH
    Anticancer Res; 2001; 21(4A):2649-55. PubMed ID: 11724334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2.
    Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
    Int J Oncol; 2009 Jan; 34(1):43-51. PubMed ID: 19082476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
    Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
    Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1.
    Chen A; Xu J; Johnson AC
    Oncogene; 2006 Jan; 25(2):278-87. PubMed ID: 16170359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
    Dorai T; Gehani N; Katz A
    Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
    Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR.
    Chen A; Xu J
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G447-56. PubMed ID: 15486348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
    Qian X; O'Rourke DM; Zhao H; Greene MI
    Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
    Wildenhain Y; Pawson T; Blackstein ME; Andrulis IL
    Oncogene; 1990 Jun; 5(6):879-83. PubMed ID: 1694290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
    Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.